CYP1A1 gene polymorphism and heavy metal analyses in benign prostatic hyperplasia and prostate cancer: An explorative case-control study.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
08 2023
Historique:
received: 03 11 2022
revised: 19 04 2023
accepted: 24 04 2023
medline: 31 7 2023
pubmed: 6 6 2023
entrez: 5 6 2023
Statut: ppublish

Résumé

The prostatic disorder is associated with benign prostatic hyperplasia (BPH) and prostate cancer (CaP). Evidently, prevalent transcription factors and signaling pathways define their relationship. The etiology of the prostatic disorder is multifactorial including heavy metal toxicity like lead (Pb), Cadmium (Cd), and genetic factors. This study elucidates the association between heavy metal toxicity Pb, Cd, and CYP1A1 gene polymorphism with BPH and CaP. a case-control study with (BPH, n = 104), (CaP, n = 58) and (controls, n =107) patients. Heavy metal Pb and Cd estimation by atomic absorption spectrophotometer. The polymorphism of the CYP1A1 T>C (rs4646903) gene was analyzed byPCR-RFLP. Higher levels of Pb and Cd were found in BPH and CaP followed by the control group (P-value: < 0.05). Pb and Cd show a significant correlation among prostate volume in CaP. Additionally, PSA, IPSS score, and pre void volume were positively co-related with Pb in BPH patients. The posthoc test defines the level of Pb and Cd as significantly elevated in the mutant genotype, highest among homozygous mutant genotype of CYP1A1gene among BPH. In CaP, Pb is significantly higher among the homozygous mutant type of CYP1A1 gene. The risk is also influenced by smoking, tobacco, and alcohol. The heavy metal toxicity Pb and Cd were reported to raise the risk of BPH and CaP. However, a person with heavy metal toxicity especially in BPH has a high-risk genetic susceptibility to the CYP1A1 gene in the north Indian population.

Identifiants

pubmed: 37277283
pii: S1078-1439(23)00142-4
doi: 10.1016/j.urolonc.2023.04.022
pii:
doi:

Substances chimiques

Cytochrome P-450 CYP1A1 EC 1.14.14.1
Cadmium 00BH33GNGH
Lead 2P299V784P
Prostate-Specific Antigen EC 3.4.21.77
CYP1A1 protein, human EC 1.14.14.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

355.e9-355.e17

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interests.

Auteurs

Vishwajeet Singh (V)

Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. Electronic address: drvishwajeet68@gmail.com.

Amit Kumar Madeshiya (AK)

Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India; Faillace Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center, Houston, TX.

Nasreen Ghazi Ansari (NG)

Regulatory Toxicology, CSIR-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India.

Mukul Kumar Singh (MK)

Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India.

Amar Abhishek (A)

School of Life sciences, Guru Ghasidas vishwavidyalaya, A Central University, Bilaspur, Chattisgarh, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH